Seer, Inc.
Seer, Inc. develops the Proteograph Product Suite, a life sciences platform used to prepare and analyze proteins for deep proteomics research. The company is based in Redwood City, California and sells instruments, consumables, and related services to research and commercial customers in North America, Europe, and Asia Pacific.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueProteograph-enabled automation and instrument systems used to run the workflow.
Assay kits, nanoparticles, reagents, and related workflow consumables.
Fee-for-service proteomic data generation, analysis, and access programs.
Shipping revenue, lease arrangements, and related-party activity.
Customers
Seer sells primarily to commercial companies, academic institutions, and other research organizations that need proteomics data for discovery and translational research. Its customer base also includes related-party and strategic collaborators, and the company notes that revenue has been concentrated in a small number of customers. Customers buy the platform to access unbiased protein analysis, reduce workflow complexity, and avoid the capital burden of owning the instrument outright.
Buy Proteograph instruments, consumables, and services to support internal R&D and biomarker discovery.
Use the platform for population-scale and translational proteomics studies funded by grants.
Access Proteograph workflows through STAC when they want data without owning the system.
Buy products and services through collaboration or related-party arrangements such as PrognomiQ.
Strategy
Seer’s strategy is to broaden adoption of Proteograph by lowering access barriers and expanding the number of ways customers can use the platform. The company is building direct sales, service centers, channel partnerships, and commercial programs such as SIPP and STAC to make the workflow easier to trial, adopt, and scale. It also continues to expand manufacturing and product capabilities to support broader commercial availability and international growth.
The business depends on converting scientific interest into recurring product and service usage.
Reducing capex and workflow friction can accelerate trial and repeat usage.
Broader availability requires reliable production of consumables and instruments.
International markets can diversify demand and broaden the installed base.
Geography
Seer is headquartered in the United States and generates most of its revenue domestically. It maintains direct sales and customer support in North America, the United Kingdom, selected EU countries, and Asia Pacific, while also using international channel partners and service centers such as STAC in Germany. Geography matters because the company’s commercial rollout depends on local scientific adoption, logistics for temperature-sensitive consumables, and access to research funding in each market.
Risks
Seer is an early-stage commercial life sciences company with concentrated customers, limited operating history, and dependence on research spending. Its business also depends on successful commercialization, reliable third-party manufacturing and logistics, and continued scientific validation of the Proteograph platform. As with many analytical instrument companies, adoption risk, funding cycles, intellectual property disputes, and supply chain disruptions can materially affect results.
- Dependence on research fundingImpact: HighLikelihood: High
Customers often rely on government or grant funding, so lower R&D budgets can reduce demand.
Exposure: Academic and research institutions
- Commercialization executionImpact: HighLikelihood: High
The company must build market acceptance for a specialized proteomics platform.
Exposure - Customer concentrationImpact: HighLikelihood: Medium
A small number of customers account for a meaningful share of revenue, so lost orders can quickly reduce sales.
Exposure: PrognomiQ and other early commercial accounts
- Supply chain and manufacturing disruptionImpact: MediumLikelihood: Medium
Instruments and consumables rely on third-party manufacturing and sourced components.
Exposure: Hamilton-made SP200 instruments and outsourced inputs
- Intellectual property litigationImpact: MediumLikelihood: Low
Proteomics tools can face infringement claims that affect product availability and cost.
Exposure: Platform technology and assay workflow
Accounting
Judgemental itemsThe company sells instruments, consumables, and services, so contract allocation and timing matter.
Impact: Can shift revenue between periods and between product and service lines
Revenue includes sales and services to related parties such as PrognomiQ.
Impact: Can affect concentration analysis and comparability
SIPP and similar arrangements may involve instrument loans and consumable commitments.
Impact: Can change revenue timing and asset classification
Consumables and proprietary nanoparticles require judgment on obsolescence and production costs.
Impact: Can affect gross margin and inventory carrying values
Other income includes investment-related gains and losses.
Impact: Can create volatility outside core operating performance
Similar listed companies
Publicly listed companies with a comparable business focus.
Strategic Environmental & Energy Resources, Inc.
SENR · Hazardous Waste Management
Nautilus Biotechnology, Inc.
NAUT · Laboratory Analytical Instruments
Standard BioTools Inc
LAB · Pharmaceutical Preparations
Sera Prognostics, Inc
SERA · Services-Medical Laboratories
Ouster, Inc.
OUST · General Industrial Machinery & Equipment, NEC
Quanterix Corp
QTRX · Laboratory Analytical Instruments
Quanterix Corp develops and commercializes ultra-sensitive life science instruments, assay kits, and related services used to measure proteins and biomarkers in biological samples.
Last updated: 24/09/2026